Search EMPEROR-Preserved: Primary Endpoint and Key Quality of Life Results With Empagliflozin vs Placebo in Patients With LVEF ≥50% Source: Innovations in Heart Failure: Highlights and Insights From AHA 2021* DOWNLOAD SLIDESET November 13-15, 2021; Virtual Significant improvement vs placebo in composite primary endpoint even in patients with “true” HFpEF. Format: Microsoft PowerPoint (.ppt) File Size: 246 KB Released: December 2, 2021 Acknowledgements Provided by Clinical Care Options, LLC. Contact Info Supported by an educational grant from Merck Program Contents AHA 2021 Capsule Summary Slidesets (3) Canagliflozin HF Symptoms HF Early Relapse Detection Empagliflozin LVEF ≥50% ClinicalThought (Coming Soon) Related Content Slideset Slideset CHIEF-HF: Improvement in Heart Failure Symptoms at 12 Wk With Canagliflozin vs Placebo VIEW SLIDESET VIEW MORE Slideset Slideset Cardiac Imaging Key to Detecting Early Relapse After Withdrawal of Heart Failure Medications in Patients In Remission VIEW SLIDESET VIEW MORE Slideset Slideset Ushering in a New Era of Sustainable Weight Loss with Incretin-Based Therapies VIEW SLIDESET VIEW MORE Text Module Text Module ACC 2021: Key Studies Affecting Clinical Care of Heart Failure CME VIEW TEXT MODULE VIEW MORE User Resources Profile Contact Us Help Site Requirements Privacy Policy Terms of Use Educational Formats Topics Programs Conference Coverage ClinicalThought Podcast Slides Tools Specialty Sites Cardiology Endocrinology Health Disparities Hepatitis HIV Immunology Infectious Disease Internal Medicine Neurology/Psychiatry Oncology Pulmonology Other CCO Sites CCO inPractice About CCO Disclaimer: The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials. © 2021 Clinical Care Options, LLC. All rights reserved. Cookie Preferences